http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 04 Sep 2026 06:07:13 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Intl+Ratings/BofA+Securities+Reiterates+Buy+Rating+on+Merck+KGaA+%28MRK%3AGR%29+%28MKGAF%29/27027344.html <p>BofA Securities analyst Sachin Jain reiterated a Buy rating and EUR155.00 price target on Merck KGaA (MRK:GR) (OTC: MKGAF).</p> http://www.streetinsider.com/Intl+Ratings/BofA+Securities+Reiterates+Buy+Rating+on+Merck+KGaA+%28MRK%3AGR%29+%28MKGAF%29/27027344.html Fri, 04 Sep 2026 06:07:13 -0400 MKGAF http://www.streetinsider.com/Intl+Ratings/BofA+Securities+Reiterates+Buy+Rating+on+Merck+KGaA+%28MRK%3AGR%29+%28MKGAF%29/27027344.html <p>BofA Securities analyst Sachin Jain reiterated a Buy rating and EUR155.00 price target on Merck KGaA (MRK:GR) (OTC: MKGAF).</p> http://www.streetinsider.com/Intl+Ratings/BofA+Securities+Reiterates+Buy+Rating+on+Merck+KGaA+%28MRK%3AGR%29+%28MKGAF%29/27027344.html Fri, 04 Sep 2026 06:07:13 -0400 MKGAF http://www.streetinsider.com/Intl+Ratings/HSBC+Upgrades+Merck+KGaA+%28MRK%3AGR%29+%28MKGAF%29+to+Buy/27007467.html <p>HSBC analyst Rajesh Kumar upgraded Merck KGaA (MRK:GR) (OTC: MKGAF) from Hold to Buy with a price target of EUR170.00.</p><p>The analyst comments: “Whilst LS growth for the next four quarters is likely to be below the H1 run-rate, we think the run-rate should not raise questions regarding structural growth if peers are accelerating and comp effects for Merck are well understood. Moreover, we think electronics acceleration should offset some of the impact from tools. Second, we think Merck is usually quite prudent with M&A. Our analysis of Bio-Techne deal leaves us unconvinced regarding the return accretion potential even with the http://www.streetinsider.com/Intl+Ratings/HSBC+Upgrades+Merck+KGaA+%28MRK%3AGR%29+%28MKGAF%29+to+Buy/27007467.html Tue, 01 Sep 2026 02:12:41 -0400 MKGAF http://www.streetinsider.com/Upgrades/HSBC+Upgrades+Merck+KGaA+%28MRK%3AGR%29+%28MKGAF%29+to+Buy/27007467.html <p>HSBC analyst Rajesh Kumar upgraded Merck KGaA (MRK:GR) (OTC: MKGAF) from Hold to Buy with a price target of EUR170.00.</p><p>The analyst comments: “Whilst LS growth for the next four quarters is likely to be below the H1 run-rate, we think the run-rate should not raise questions regarding structural growth if peers are accelerating and comp effects for Merck are well understood. Moreover, we think electronics acceleration should offset some of the impact from tools. Second, we think Merck is usually quite prudent with M&A. Our analysis of Bio-Techne deal leaves us unconvinced regarding the return accretion potential even with the http://www.streetinsider.com/Upgrades/HSBC+Upgrades+Merck+KGaA+%28MRK%3AGR%29+%28MKGAF%29+to+Buy/27007467.html Tue, 01 Sep 2026 02:12:41 -0400 MKGAF http://www.streetinsider.com/Analyst+Comments/HSBC+Upgrades+Merck+KGaA+%28MRK%3AGR%29+%28MKGAF%29+to+Buy/27007467.html <p>HSBC analyst Rajesh Kumar upgraded Merck KGaA (MRK:GR) (OTC: MKGAF) from Hold to Buy with a price target of EUR170.00.</p><p>The analyst comments: “Whilst LS growth for the next four quarters is likely to be below the H1 run-rate, we think the run-rate should not raise questions regarding structural growth if peers are accelerating and comp effects for Merck are well understood. Moreover, we think electronics acceleration should offset some of the impact from tools. Second, we think Merck is usually quite prudent with M&A. Our analysis of Bio-Techne deal leaves us unconvinced regarding the return accretion potential even with the http://www.streetinsider.com/Analyst+Comments/HSBC+Upgrades+Merck+KGaA+%28MRK%3AGR%29+%28MKGAF%29+to+Buy/27007467.html Tue, 01 Sep 2026 02:12:41 -0400 MKGAF http://www.streetinsider.com/Intl+Ratings/HSBC+Upgrades+Merck+KGaA+%28MRK%3AGR%29+%28MKGAF%29+to+Buy/27007467.html <p>HSBC analyst Rajesh Kumar upgraded Merck KGaA (MRK:GR) (OTC: MKGAF) from Hold to Buy with a price target of EUR170.00.</p><p>The analyst comments: “Whilst LS growth for the next four quarters is likely to be below the H1 run-rate, we think the run-rate should not raise questions regarding structural growth if peers are accelerating and comp effects for Merck are well understood. Moreover, we think electronics acceleration should offset some of the impact from tools. Second, we think Merck is usually quite prudent with M&A. Our analysis of Bio-Techne deal leaves us unconvinced regarding the return accretion potential even with the http://www.streetinsider.com/Intl+Ratings/HSBC+Upgrades+Merck+KGaA+%28MRK%3AGR%29+%28MKGAF%29+to+Buy/27007467.html Tue, 01 Sep 2026 02:12:41 -0400 MKGAF http://www.streetinsider.com/Upgrades/HSBC+Upgrades+Merck+KGaA+%28MRK%3AGR%29+%28MKGAF%29+to+Buy/27007467.html <p>HSBC analyst Rajesh Kumar upgraded Merck KGaA (MRK:GR) (OTC: MKGAF) from Hold to Buy with a price target of EUR170.00.</p><p>The analyst comments: “Whilst LS growth for the next four quarters is likely to be below the H1 run-rate, we think the run-rate should not raise questions regarding structural growth if peers are accelerating and comp effects for Merck are well understood. Moreover, we think electronics acceleration should offset some of the impact from tools. Second, we think Merck is usually quite prudent with M&A. Our analysis of Bio-Techne deal leaves us unconvinced regarding the return accretion potential even with the http://www.streetinsider.com/Upgrades/HSBC+Upgrades+Merck+KGaA+%28MRK%3AGR%29+%28MKGAF%29+to+Buy/27007467.html Tue, 01 Sep 2026 02:12:41 -0400 MKGAF http://www.streetinsider.com/Analyst+Comments/HSBC+Upgrades+Merck+KGaA+%28MRK%3AGR%29+%28MKGAF%29+to+Buy/27007467.html <p>HSBC analyst Rajesh Kumar upgraded Merck KGaA (MRK:GR) (OTC: MKGAF) from Hold to Buy with a price target of EUR170.00.</p><p>The analyst comments: “Whilst LS growth for the next four quarters is likely to be below the H1 run-rate, we think the run-rate should not raise questions regarding structural growth if peers are accelerating and comp effects for Merck are well understood. Moreover, we think electronics acceleration should offset some of the impact from tools. Second, we think Merck is usually quite prudent with M&A. Our analysis of Bio-Techne deal leaves us unconvinced regarding the return accretion potential even with the http://www.streetinsider.com/Analyst+Comments/HSBC+Upgrades+Merck+KGaA+%28MRK%3AGR%29+%28MKGAF%29+to+Buy/27007467.html Tue, 01 Sep 2026 02:12:41 -0400 MKGAF http://www.streetinsider.com/Intl+Ratings/Merck+KGaA+%28MRK%3AGR%29+%28MKGAF%29+PT+Raised+to+EUR140+at+Barclays/26803433.html Barclays analyst Charles Pitman-King raised the price target on Merck KGaA (MRK:GR) (OTC: MKGAF) to EUR140.00 (from EUR135.00) while maintaining a Equalweight rating. http://www.streetinsider.com/Intl+Ratings/Merck+KGaA+%28MRK%3AGR%29+%28MKGAF%29+PT+Raised+to+EUR140+at+Barclays/26803433.html Thu, 23 Jul 2026 05:07:33 -0400 MKGAF http://www.streetinsider.com/Analyst+PT+Change/Merck+KGaA+%28MRK%3AGR%29+%28MKGAF%29+PT+Raised+to+EUR140+at+Barclays/26803433.html Barclays analyst Charles Pitman-King raised the price target on Merck KGaA (MRK:GR) (OTC: MKGAF) to EUR140.00 (from EUR135.00) while maintaining a Equalweight rating. http://www.streetinsider.com/Analyst+PT+Change/Merck+KGaA+%28MRK%3AGR%29+%28MKGAF%29+PT+Raised+to+EUR140+at+Barclays/26803433.html Thu, 23 Jul 2026 05:07:33 -0400 MKGAF http://www.streetinsider.com/Intl+Ratings/Merck+KGaA+%28MRK%3AGR%29+%28MKGAF%29+PT+Raised+to+EUR140+at+Barclays/26803433.html Barclays analyst Charles Pitman-King raised the price target on Merck KGaA (MRK:GR) (OTC: MKGAF) to EUR140.00 (from EUR135.00) while maintaining a Equalweight rating. http://www.streetinsider.com/Intl+Ratings/Merck+KGaA+%28MRK%3AGR%29+%28MKGAF%29+PT+Raised+to+EUR140+at+Barclays/26803433.html Thu, 23 Jul 2026 05:07:33 -0400 MKGAF http://www.streetinsider.com/Analyst+PT+Change/Merck+KGaA+%28MRK%3AGR%29+%28MKGAF%29+PT+Raised+to+EUR140+at+Barclays/26803433.html Barclays analyst Charles Pitman-King raised the price target on Merck KGaA (MRK:GR) (OTC: MKGAF) to EUR140.00 (from EUR135.00) while maintaining a Equalweight rating. http://www.streetinsider.com/Analyst+PT+Change/Merck+KGaA+%28MRK%3AGR%29+%28MKGAF%29+PT+Raised+to+EUR140+at+Barclays/26803433.html Thu, 23 Jul 2026 05:07:33 -0400 MKGAF http://www.streetinsider.com/Analyst+PT+Change/HSBC+Downgrades+Merck+KGaA+%28MRK%3AGR%29+%28MKGAF%29+to+Hold/26731449.html (Updated - July 6, 2026 5:41 AM EDT) <p>HSBC analyst Rajesh Kumar downgraded Merck KGaA (MRK:GR) (OTC: MKGAF) from Buy to Hold with a price target of EUR170.00 (from EUR160.00).</p><p>The analyst comments: “Our bull case on Merck was premised on rerating with Life Science tools recovery and potential for reinvestment in deal flows. The recovery of Process solutions has been better than expected, partially due to pull forward of demand due to stocking as customers de-risked their supply chain to just-in-case inventory build around the Middle East conflict. We think these tailwinds might persist until 3Q26 but followed by a period http://www.streetinsider.com/Analyst+PT+Change/HSBC+Downgrades+Merck+KGaA+%28MRK%3AGR%29+%28MKGAF%29+to+Hold/26731449.html Mon, 06 Jul 2026 05:41:59 -0400 MKGAF http://www.streetinsider.com/Downgrades/HSBC+Downgrades+Merck+KGaA+%28MRK%3AGR%29+%28MKGAF%29+to+Hold/26731449.html (Updated - July 6, 2026 5:41 AM EDT) <p>HSBC analyst Rajesh Kumar downgraded Merck KGaA (MRK:GR) (OTC: MKGAF) from Buy to Hold with a price target of EUR170.00 (from EUR160.00).</p><p>The analyst comments: “Our bull case on Merck was premised on rerating with Life Science tools recovery and potential for reinvestment in deal flows. The recovery of Process solutions has been better than expected, partially due to pull forward of demand due to stocking as customers de-risked their supply chain to just-in-case inventory build around the Middle East conflict. We think these tailwinds might persist until 3Q26 but followed by a period http://www.streetinsider.com/Downgrades/HSBC+Downgrades+Merck+KGaA+%28MRK%3AGR%29+%28MKGAF%29+to+Hold/26731449.html Mon, 06 Jul 2026 05:41:59 -0400 MKGAF http://www.streetinsider.com/Intl+Ratings/HSBC+Downgrades+Merck+KGaA+%28MRK%3AGR%29+%28MKGAF%29+to+Hold/26731449.html (Updated - July 6, 2026 5:41 AM EDT) <p>HSBC analyst Rajesh Kumar downgraded Merck KGaA (MRK:GR) (OTC: MKGAF) from Buy to Hold with a price target of EUR170.00 (from EUR160.00).</p><p>The analyst comments: “Our bull case on Merck was premised on rerating with Life Science tools recovery and potential for reinvestment in deal flows. The recovery of Process solutions has been better than expected, partially due to pull forward of demand due to stocking as customers de-risked their supply chain to just-in-case inventory build around the Middle East conflict. We think these tailwinds might persist until 3Q26 but followed by a period http://www.streetinsider.com/Intl+Ratings/HSBC+Downgrades+Merck+KGaA+%28MRK%3AGR%29+%28MKGAF%29+to+Hold/26731449.html Mon, 06 Jul 2026 05:41:59 -0400 MKGAF http://www.streetinsider.com/Analyst+Comments/HSBC+Downgrades+Merck+KGaA+%28MRK%3AGR%29+%28MKGAF%29+to+Hold/26731449.html (Updated - July 6, 2026 5:41 AM EDT) <p>HSBC analyst Rajesh Kumar downgraded Merck KGaA (MRK:GR) (OTC: MKGAF) from Buy to Hold with a price target of EUR170.00 (from EUR160.00).</p><p>The analyst comments: “Our bull case on Merck was premised on rerating with Life Science tools recovery and potential for reinvestment in deal flows. The recovery of Process solutions has been better than expected, partially due to pull forward of demand due to stocking as customers de-risked their supply chain to just-in-case inventory build around the Middle East conflict. We think these tailwinds might persist until 3Q26 but followed by a period http://www.streetinsider.com/Analyst+Comments/HSBC+Downgrades+Merck+KGaA+%28MRK%3AGR%29+%28MKGAF%29+to+Hold/26731449.html Mon, 06 Jul 2026 05:41:59 -0400 MKGAF http://www.streetinsider.com/Analyst+PT+Change/HSBC+Downgrades+Merck+KGaA+%28MRK%3AGR%29+%28MKGAF%29+to+Hold/26731449.html (Updated - July 6, 2026 5:41 AM EDT) <p>HSBC analyst Rajesh Kumar downgraded Merck KGaA (MRK:GR) (OTC: MKGAF) from Buy to Hold with a price target of EUR170.00 (from EUR160.00).</p><p>The analyst comments: “Our bull case on Merck was premised on rerating with Life Science tools recovery and potential for reinvestment in deal flows. The recovery of Process solutions has been better than expected, partially due to pull forward of demand due to stocking as customers de-risked their supply chain to just-in-case inventory build around the Middle East conflict. We think these tailwinds might persist until 3Q26 but followed by a period http://www.streetinsider.com/Analyst+PT+Change/HSBC+Downgrades+Merck+KGaA+%28MRK%3AGR%29+%28MKGAF%29+to+Hold/26731449.html Mon, 06 Jul 2026 05:41:59 -0400 MKGAF http://www.streetinsider.com/Downgrades/HSBC+Downgrades+Merck+KGaA+%28MRK%3AGR%29+%28MKGAF%29+to+Hold/26731449.html (Updated - July 6, 2026 5:41 AM EDT) <p>HSBC analyst Rajesh Kumar downgraded Merck KGaA (MRK:GR) (OTC: MKGAF) from Buy to Hold with a price target of EUR170.00 (from EUR160.00).</p><p>The analyst comments: “Our bull case on Merck was premised on rerating with Life Science tools recovery and potential for reinvestment in deal flows. The recovery of Process solutions has been better than expected, partially due to pull forward of demand due to stocking as customers de-risked their supply chain to just-in-case inventory build around the Middle East conflict. We think these tailwinds might persist until 3Q26 but followed by a period http://www.streetinsider.com/Downgrades/HSBC+Downgrades+Merck+KGaA+%28MRK%3AGR%29+%28MKGAF%29+to+Hold/26731449.html Mon, 06 Jul 2026 05:41:59 -0400 MKGAF http://www.streetinsider.com/Intl+Ratings/HSBC+Downgrades+Merck+KGaA+%28MRK%3AGR%29+%28MKGAF%29+to+Hold/26731449.html (Updated - July 6, 2026 5:41 AM EDT) <p>HSBC analyst Rajesh Kumar downgraded Merck KGaA (MRK:GR) (OTC: MKGAF) from Buy to Hold with a price target of EUR170.00 (from EUR160.00).</p><p>The analyst comments: “Our bull case on Merck was premised on rerating with Life Science tools recovery and potential for reinvestment in deal flows. The recovery of Process solutions has been better than expected, partially due to pull forward of demand due to stocking as customers de-risked their supply chain to just-in-case inventory build around the Middle East conflict. We think these tailwinds might persist until 3Q26 but followed by a period http://www.streetinsider.com/Intl+Ratings/HSBC+Downgrades+Merck+KGaA+%28MRK%3AGR%29+%28MKGAF%29+to+Hold/26731449.html Mon, 06 Jul 2026 05:41:59 -0400 MKGAF http://www.streetinsider.com/Analyst+Comments/HSBC+Downgrades+Merck+KGaA+%28MRK%3AGR%29+%28MKGAF%29+to+Hold/26731449.html (Updated - July 6, 2026 5:41 AM EDT) <p>HSBC analyst Rajesh Kumar downgraded Merck KGaA (MRK:GR) (OTC: MKGAF) from Buy to Hold with a price target of EUR170.00 (from EUR160.00).</p><p>The analyst comments: “Our bull case on Merck was premised on rerating with Life Science tools recovery and potential for reinvestment in deal flows. The recovery of Process solutions has been better than expected, partially due to pull forward of demand due to stocking as customers de-risked their supply chain to just-in-case inventory build around the Middle East conflict. We think these tailwinds might persist until 3Q26 but followed by a period http://www.streetinsider.com/Analyst+Comments/HSBC+Downgrades+Merck+KGaA+%28MRK%3AGR%29+%28MKGAF%29+to+Hold/26731449.html Mon, 06 Jul 2026 05:41:59 -0400 MKGAF http://www.streetinsider.com/Intl+Ratings/UBS+Reiterates+Buy+Rating+on+Merck+KGaA+%28MRK%3AGR%29+%28MKGAF%29/26694237.html <p>UBS analyst Matthew Weston reiterated a Buy rating and EUR150.00 price target on Merck KGaA (MRK:GR) (OTC: MKGAF).</p> http://www.streetinsider.com/Intl+Ratings/UBS+Reiterates+Buy+Rating+on+Merck+KGaA+%28MRK%3AGR%29+%28MKGAF%29/26694237.html Fri, 26 Jun 2026 05:40:35 -0400 MKGAF http://www.streetinsider.com/Intl+Ratings/UBS+Reiterates+Buy+Rating+on+Merck+KGaA+%28MRK%3AGR%29+%28MKGAF%29/26694237.html <p>UBS analyst Matthew Weston reiterated a Buy rating and EUR150.00 price target on Merck KGaA (MRK:GR) (OTC: MKGAF).</p> http://www.streetinsider.com/Intl+Ratings/UBS+Reiterates+Buy+Rating+on+Merck+KGaA+%28MRK%3AGR%29+%28MKGAF%29/26694237.html Fri, 26 Jun 2026 05:40:35 -0400 MKGAF http://www.streetinsider.com/Intl+Ratings/Merck+KGaA+%28MRK%3AGR%29+%28MKGAF%29+PT+Raised+to+EUR135+at+Barclays/26694194.html Barclays analyst Charles Pitman-King raised the price target on Merck KGaA (MRK:GR) (OTC: MKGAF) to EUR135.00 (from EUR130.00) while maintaining a Equalweight rating. http://www.streetinsider.com/Intl+Ratings/Merck+KGaA+%28MRK%3AGR%29+%28MKGAF%29+PT+Raised+to+EUR135+at+Barclays/26694194.html Fri, 26 Jun 2026 04:58:05 -0400 MKGAF http://www.streetinsider.com/Analyst+PT+Change/Merck+KGaA+%28MRK%3AGR%29+%28MKGAF%29+PT+Raised+to+EUR135+at+Barclays/26694194.html Barclays analyst Charles Pitman-King raised the price target on Merck KGaA (MRK:GR) (OTC: MKGAF) to EUR135.00 (from EUR130.00) while maintaining a Equalweight rating. http://www.streetinsider.com/Analyst+PT+Change/Merck+KGaA+%28MRK%3AGR%29+%28MKGAF%29+PT+Raised+to+EUR135+at+Barclays/26694194.html Fri, 26 Jun 2026 04:58:05 -0400 MKGAF http://www.streetinsider.com/Intl+Ratings/Merck+KGaA+%28MRK%3AGR%29+%28MKGAF%29+PT+Raised+to+EUR135+at+Barclays/26694194.html Barclays analyst Charles Pitman-King raised the price target on Merck KGaA (MRK:GR) (OTC: MKGAF) to EUR135.00 (from EUR130.00) while maintaining a Equalweight rating. http://www.streetinsider.com/Intl+Ratings/Merck+KGaA+%28MRK%3AGR%29+%28MKGAF%29+PT+Raised+to+EUR135+at+Barclays/26694194.html Fri, 26 Jun 2026 04:58:05 -0400 MKGAF